A black box of Generic TB-500 5 MG, labeled for laboratory research use only, sits on a white lab counter with pipettes, bottles, and other lab equipment blurred in the background.

Retatrutide

5mg
€78,00
€78,00
Skip to product information
A black box of Generic TB-500 5 MG, labeled for laboratory research use only, sits on a white lab counter with pipettes, bottles, and other lab equipment blurred in the background.
  • A black box of Generic TB-500 5 MG, labeled for laboratory research use only, sits on a white lab counter with pipettes, bottles, and other lab equipment blurred in the background.
  • A black box of Generic TB-500 5 MG, labeled for laboratory research use only, sits on a white lab counter with pipettes, bottles, and other lab equipment blurred in the background.
Retatrutide

Retatrutide

€78,00
€78,00
Size

About the Product

Genetic Labs Retatrutide is a high-purity synthetic peptide (research grade) supplied in a vial containing 20mg of lyophilized (freeze-dried) powder. Retatrutide is a novel, tri-agonist peptide that simultaneously targets three key metabolic hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R) , the glucose-dependent insulinotropic polypeptide receptor (GIPR) , and the glucagon receptor (GCGR) . This unique triple agonism represents a significant advancement in metabolic research, offering a multi-pathway approach to studying energy balance, glucose homeostasis, and lipid metabolism.

Kit Contents:

  • 1 Vial with 20mg Retatrutide (Lyophilized Powder)

  • 1 Vial with 3mL Bacteriostatic Water (Diluent)

For Laboratory Research Use Only. Not for human consumption.

Benefits (Research Scope)

  • Triple Receptor Agonist: Retatrutide is the first-in-class peptide that activates all three receptors—GLP-1R, GIPR, and GCGR—simultaneously. This unique combination allows researchers to study the synergistic effects of multiple metabolic pathways in a single compound, offering advantages over selective or dual agonists.

  • Versatile Research Tool: Suitable for a wide range of studies, including:

    • Metabolic Disorders: Research into obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD).

    • Energy Expenditure: Studies on resting energy expenditure, thermogenesis, and brown adipose tissue (BAT) activation.

    • Lipid Metabolism: Research into fatty acid oxidation, lipolysis, and lipid profiling.

    • Appetite & Body Weight: Studies on hypothalamic regulation of food intake, satiety, and sustained weight reduction.

    • Glucose Homeostasis: Investigation into insulin secretion, glucagon regulation, and glycemic control.

    • Cardiovascular Research: Studies on cardiovascular outcomes, blood pressure, and lipid profiles.

  • Practical Formulation: The lyophilized powder ensures stability and extended shelf life, while the included bacteriostatic water facilitates easy reconstitution for both in vitro and in vivo experiments.

Research & Science

Retatrutide is a groundbreaking investigational peptide that has generated significant interest in the scientific community for its multi-targeted approach to metabolic disease research.

  • Mechanism of Action: Retatrutide is a 39-amino-acid peptide engineered to bind and activate three distinct receptors:

    • GLP-1R (Glucagon-Like Peptide-1 Receptor): Stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite.

    • GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor): Enhances insulin secretion, improves lipid metabolism, and reduces adiposity.

    • GCGR (Glucagon Receptor): Increases energy expenditure, stimulates lipolysis, promotes fatty acid oxidation, and enhances thermogenesis.

  • Triple Agonism Advantage: The combination of these three pathways results in a coordinated metabolic effect that goes beyond the capabilities of GLP-1 agonists alone:

    • GLP-1R + GIPR: Enhanced insulin secretion, improved glycemic control, and synergistic weight loss effects.

    • GIPR + GCGR: Amplified lipid metabolism and energy expenditure.

    • GLP-1R + GCGR: Optimized glucose homeostasis with balanced energy utilization.

  • Preclinical Research: Studies have demonstrated that retatrutide:

    • Significantly reduces body weight and adiposity in diet-induced obesity models, with greater efficacy than GLP-1R or GIPR selective agonists.

    • Improves glycemic control with superior glucose-lowering effects compared to semaglutide.

    • Enhances lipid metabolism with reductions in triglycerides, LDL cholesterol, and hepatic steatosis.

    • Increases energy expenditure through activation of brown adipose tissue (BAT) and increased thermogenesis.

  • Clinical Research: Retatrutide has been evaluated in clinical trials, including dose-escalation studies in individuals with obesity and type 2 diabetes, demonstrating:

    • Substantial weight loss (up to 24% reduction in body weight in clinical trials).

    • Significant improvements in glycemic control and HbA1c reduction.

    • Favorable cardiovascular and renal outcome profiles.

    • The unique triple agonist mechanism may contribute to greater metabolic benefits compared to current GLP-1-based therapies.

  • Neuroprotective Research: Emerging research is exploring retatrutide's potential in neurodegenerative diseases, as GLP-1R and GIPR are expressed in the brain, and their activation has been shown to reduce neuroinflammation and improve cognitive function.

  • Focus on Genetic Variability: Current research is investigating how genetic polymorphisms in GLP1R, GIPR, GCGR, and other metabolic pathway genes may influence individual responses to retatrutide, providing insights for personalized metabolic interventions.

Important Note on Kit Contents

Please verify the kit contents as listed in the image:

  • 1 x Vial Retatrutide (Lyophilized Powder) 20mg

  • 1 x Vial Bacteriostatic Water (Diluent) 3mL (Note: The text in the image appears to have a typo. It should read "Bacteriostatic Water" as per standard practice.)

You may also like